{"name":"Hansoh BioMedical R&D Company","slug":"hansoh-biomedical-r-d-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"HS-20093","genericName":"HS-20093","slug":"hs-20093","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Gemcitabine combined with docetaxel","genericName":"Gemcitabine combined with docetaxel","slug":"gemcitabine-combined-with-docetaxel","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HS-20089","genericName":"HS-20089","slug":"hs-20089","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"HS-20137","genericName":"HS-20137","slug":"hs-20137","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"HS-10374-matched placebo tablets","genericName":"HS-10374-matched placebo tablets","slug":"hs-10374-matched-placebo-tablets","indication":"Other","status":"phase_3"},{"name":"HS-10390","genericName":"HS-10390","slug":"hs-10390","indication":"Other","status":"phase_2"},{"name":"Placebo&HS-20137","genericName":"Placebo&HS-20137","slug":"placebo-hs-20137","indication":"Other","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Drospirenone and Ethinyl Estradiol tablets","genericName":"Drospirenone and Ethinyl Estradiol tablets","slug":"drospirenone-and-ethinyl-estradiol-tablets","indication":"Oral contraception for prevention of pregnancy","status":"marketed"}]}],"pipeline":[{"name":"HS-10374-matched placebo tablets","genericName":"HS-10374-matched placebo tablets","slug":"hs-10374-matched-placebo-tablets","phase":"phase_3","mechanism":"This is a placebo tablet formulation used as a control comparator in clinical trials of HS-10374.","indications":[],"catalyst":""},{"name":"HS-20093","genericName":"HS-20093","slug":"hs-20093","phase":"phase_3","mechanism":"HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Drospirenone and Ethinyl Estradiol tablets","genericName":"Drospirenone and Ethinyl Estradiol tablets","slug":"drospirenone-and-ethinyl-estradiol-tablets","phase":"marketed","mechanism":"Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.","indications":["Oral contraception for prevention of pregnancy","Treatment of acne vulgaris (in some formulations)","Treatment of premenstrual dysphoric disorder (PMDD)"],"catalyst":""},{"name":"Gemcitabine combined with docetaxel","genericName":"Gemcitabine combined with docetaxel","slug":"gemcitabine-combined-with-docetaxel","phase":"phase_3","mechanism":"Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells.","indications":["Non-small cell lung cancer","Breast cancer","Ovarian cancer","Pancreatic cancer"],"catalyst":""},{"name":"HS-10390","genericName":"HS-10390","slug":"hs-10390","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20089","genericName":"HS-20089","slug":"hs-20089","phase":"phase_3","mechanism":"HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HS-20137","genericName":"HS-20137","slug":"hs-20137","phase":"phase_3","mechanism":"HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Placebo&HS-20137","genericName":"Placebo&HS-20137","slug":"placebo-hs-20137","phase":"phase_3","mechanism":"HS-20137 is a small molecule with an unknown mechanism of action.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOSGZFczVxV3p5SGpVT3lwOFpJSjlyQlNjMU1CWm52SDFKTGdQakp6VjBVVndQcTdsZ1puOU1ueEhWTXFTZV9pSXBhZnlqb1RTV05vX1hXenBxWU95T1lMRkNlN0xOT1JoT0doWGF5VDE5eDh2SlJZWFdEakFMd2g2WHRacVNLYW9CbmFjVllMZXRxYmZzbjhXaEl6Q0lkeUpSdzFSOUNYc3E5SUVGRk5TX2hMQ0I1bUFYdzJXMWxjeS1qWGYxTjlxQUpxUW5tQQ?oc=5","date":"2026-01-22","type":"deal","source":"Investing.com","summary":"Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights - Investing.com","headline":"Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNUnl2bEw4NEpoSnVqMlFSbkFuSkN3OHp6VzhHMWZ4NzhuMVBzZHIxbm9SRVlmeEw3OUp6SklTU1MzTkJzNXdFNlFZUEZ3X0dSNGl5bkRzZUZnVGljNlRPYjdsY3FGT0RTMW9CVWhsNURzYUp6VjVJajlKUDM0QV9qYkt2aUdiM1VlNTVEcm14cjBPVnF6R1dobDJWYU8xQm5iRmFPS25JNWRhRlNKaVBNemlWbUJVOWxMNU1yQTln0gG-AUFVX3lxTE5WUTM4bU51MDdFUUM5emptLTlCeUxvV3hYZjNmdktEdkVDU2czNk84VnBsc08tOFZWcVp3a0w5anlIT1kxTXctRW14MEtmeWY5R3FoQkJqY1pBcnJhRVJuQlVtcmxPZ21HdkNWdXA5c3dXU2hLQlQ4X2g3UkJVZHFwXzlHSHdHVW9USHhoVmpRN0cybGxDaXdIQkN6bWpqczNBdFk1SkFZcm5sMktZQ1NVODVWOGJzSmZmMTJlSFE?oc=5","date":"2025-08-18","type":"earnings","source":"South China Morning Post","summary":"Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits - South China Morning Post","headline":"Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbXRYRG9qb3JJQmp6OGVjZHgyd0t2WTBrVXR3SFkzd0RFMWpaT2lhdVRVYmNqalZwbEZ3bE9wX0ZKT0p1VmRWeHFNYjl6VVdZX2twYkJHSzFQbU1qSVRYTGJfa0J1UHZsbFQwTXVQWWNiRkphSDdod3lzVU9aWkk1cVJtMTFtVDJa?oc=5","date":"2025-07-22","type":"pipeline","source":"BioWorld News","summary":"For big pharma, China is a shopper’s dream - BioWorld News","headline":"For big pharma, China is a shopper’s dream","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQMzVKMHBnQUdEbGlDWnhudTN3WW1VNEluNE5ZRUs2MmZaaDFzUHE4UGcyM0QzRXFINGxfR1hydU9pdko4aE5UNkhNWFJYTDJrVDYyMjBENENCZlUzTGQwYzFYRWIyclJzdHg4Qy1ZVTZROTk1WTZyamxFM3JrbzlzR2xVYjg0YmtacTBMOHZHWjJwLVp0dUhIS2hPc21IVjJKNVJfRVRRZw?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B - BioWorld News","headline":"Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOR2Rkek42XzNJRGVvaTBYcUEza3RxeV9ZM0dnMmRMV2Nlb1lvVHF3cklXTEZLeEJoNmF4dGh1b0VJM01hMTZudU5YWWZDWnAtR1FHS1R5MTlmWlJJcE8yeEtxVjRpNFh4ZzZQWTZlQ1NQWXVLelhsMzRPSGJiUF9HUVZSdDB0aThVaXFMTWxBR2g1Rmxsb25NXzFSNGpZb2xZYmxKb1c4Y29Ddw?oc=5","date":"2024-12-20","type":"regulatory","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod - Fierce Pharma","headline":"Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNb0FhUi1vcnFjeXg0S1NkY0NoZm5xcEhfX0EzQ1Z1ZHFHU0JqNkF6MDF6bU5wNS1ZazFTdG5HUVFuNHZBM0JqVDlQdEU1djBYTVpEMEZPOG05VFA0QlFEMGhuRXJiV01PSmhJQVVnNUxrYjFLeENjYkwycjZCWkZHWmUzY0syUC1vZk1Odzc1NlFjdDZoeGctdWxwc0xrWG1MeVpZeWZKNmk3NnA5LVNjdDFGNm9QSFM0dVkwU3lB?oc=5","date":"2024-12-18","type":"pipeline","source":"Contract Pharma","summary":"Merck Enters Exclusive Alliance with Hansoh Pharma for Oral GLP-1 Candidate - Contract Pharma","headline":"Merck Enters Exclusive Alliance with Hansoh Pharma for Oral GLP-1 Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQWx5NDZjbjFXb05xYkxHc2sxOFp0c3NCZy1yb21yQTJuTUdYelJGV01CMHhYRjE5NUQwaDNLM3g4SDNjTnpCMlZZVldwMTVUM0Q1XzVwbmFhbmhjRnQzdW9LUFlUYzBTR3pGaTZVanlKWkZ3LTBqX3k3c0N4clI1R3k2UnBJZ0xtbThMYmllZWhKdjczYzJGeHdzMTY4NWhVQ21xSjlLZ3p5SlBuXzlPTloxcV85bmhndkJXRg?oc=5","date":"2024-03-15","type":"deal","source":"Contract Pharma","summary":"Biotheus and Hansoh Pharma Expand Collaboration for Novel Cancer Treatment - Contract Pharma","headline":"Biotheus and Hansoh Pharma Expand Collaboration for Novel Cancer Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOemF2X01aMzhfaHZNZ1RfTzB2Zlh6alQxZ0dITHN3aVQ1NElRcEpyZEhxaTd1eWlZY09QRURNZ1FXR3o0ZHE4bWk5NEw5X2RwWnZJZVpWbENkcHY0c1VJZlBnU21pNTNscDl6NU9UUzhIX0k0YlNYNGZLUGswUWVMR0R1YnVFLVJtdkxWT0Ria1c?oc=5","date":"2024-02-28","type":"pipeline","source":"Yahoo Finance","summary":"Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key Companies - Estetra, Bayer, Hansoh BioMedical R&D Company, Mitsubishi Tanabe Pharma, Astel","headline":"Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key Companies ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQeDc5SWQ5U0dCSXpRdVdkVUdXYXl4V1BoT2FOVllqZG9YcXA4a1RDYndodDVBZ2c0ZmJxQWY2Y0xpaXZockw0Y3dES3NKTkx6LWltbDBZY3g1RGJmUVdjRHlLNnF1NDdXLVU3cXFJUXAySTJ2d3Uwd09ONGNBOVhiWkU0OHZKT3JmNHRHYW1jME5ScDlNai14VktjUjF5T3BFOGpRbGZZOXNGVDRsMHZNNg?oc=5","date":"2023-12-20","type":"deal","source":"GSK","summary":"GSK enters exclusive license agreement with Hansoh for HS-20093 - GSK","headline":"GSK enters exclusive license agreement with Hansoh for HS-20093","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZ283SlZDSlNJZzhSeXJhVElrRl9nZmpiQW16ckV6c3c1djNrU1d0OGFfYk9LTGJmQ2x2X29jdDNmcDctU0pxTnFPd0VvRzZ6ZnZVcmxzUUJEOUJwejdyOUtZTjJtb0Q4cGFjZXR2cVN5em9KdWZyWFQzeVpfVzhXaEVnUUtnRjhheHFDa2o4T0VyUmNIZzdkQmg2SGIxemxRQXhabFctV0tkNzJCZWhieg?oc=5","date":"2023-10-20","type":"deal","source":"GSK","summary":"GSK enters exclusive license agreement with Hansoh for HS-20089 - GSK","headline":"GSK enters exclusive license agreement with Hansoh for HS-20089","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":6,"marketed":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}